Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takara BioFRA:TF2 50 Return-on-Tangible-Asset is 0.07% as of Mar. 2026, which is 99% below its 10-year median of 5.09. GuruFocus rates FRA:TF2 with a GF Score™ of 50/100 and a GF Value™ of €4.48. The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Takara Bio ranks better than 72.05% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Takara Bio's annualizedNet Income for the quarter that ended in Mar. 2026 was €0.4 Mil. Takara Bio's average total tangible assets for the quarter that ended in Mar. 2026 was €588.3 Mil. Therefore, Takara Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.07%.
The historical rank and industry rank for Takara Bio's Return-on-Tangible-Asset or its related term are showing as below:
FRA:TF2'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.8 Med: 5.09 Max: 21.24
Current: -8.8
During the past 13 years, Takara Bio's highest Return-on-Tangible-Asset was 21.24%. The lowest was -8.80%. And the median was 5.09%.
FRA:TF2's Return-on-Tangible-Asset is ranked better than 72.05% of 1417
companies
in the Biotechnology industry
Industry Median: -36.06
vs FRA:TF2: -8.80
Takara Bio (FRA:TF2) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Takara Bio Return-on-Tangible-Asset Related Terms
Takara Bio Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Takara Bio's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Takara Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Takara Bio's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.07% mean?
Takara Bio (FRA:TF2) has a Return-on-Tangible-Asset of 0.07% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Takara Bio and its competitors. This is 99% below median its historical median of 5.09. According to the industry distribution chart, Takara Bio ranks #396 out of 1417 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Takara Bio's Return-on-Tangible-Asset too high?
Takara Bio's current Return-on-Tangible-Asset of 0.07% is 99% below median its 10-year median of 5.09. Based on the distribution chart, Takara Bio ranks #396 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #396 out of 1417 companies for Return-on-Tangible-Asset. This puts Takara Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Takara Bio and its competitors. Takara Bio's current Return-on-Tangible-Asset is 0.07%, which is 99% below median its own 10-year median of 5.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current Return-on-Tangible-Asset of 0.07%. The stock's GF Value™ is €4.48, compared to a current price of €5.95 — trading 32.8% above its estimated fair value. The current Return-on-Tangible-Asset is 0.07%, which is 99% below median its 10-year median of 5.09. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Return-on-Tangible-Asset is 0.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 32.8% above its estimated GF Value™ of €4.48.
Key valuation signals for FRA:TF2:
Return-on-Tangible-Asset: 0.07% (99% below median its 10-year median of 5.09)
GF Value™: €4.48 vs. price of €5.95 (32.8% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score
Get the complete analysis for FRA:TF2
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
